Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.

Authors

James G Krueger
Leon Kircik
Firas Hougeir
Adam Friedman, George Washington UniversityFollow
Xiaojun You
Nisha Lucas
Steven J Greenberg
Marianne Sweetser
Wanda Castro-Borrero
Peter McCroskery
Jacob Elkins

Document Type

Journal Article

Publication Date

6-1-2016

Journal

Advances in Therapy

DOI

10.1007/s12325-016-0353-2

APA Citation

Krueger, J., Kircik, L., Hougeir, F., Friedman, A., You, X., Lucas, N., Greenberg, S., Sweetser, M., Castro-Borrero, W., McCroskery, P., & Elkins, J. (2016). Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis.. Advances in Therapy, (). http://dx.doi.org/10.1007/s12325-016-0353-2

Peer Reviewed

1